古典的ファブリー病におけるAMT-191の安全性、PK/PD、および探索的有効性研究
古典的ファブリー病の成人男性を対象とした静脈内 AAV5-GLA (AMT-191) の第 1/2 相単回用量漸増研究
The main goals of this clinical study are to characterize safety and PK/PD of AMT-191 i.e. if drug doses used in the study are safe and tolerable and to understand how it acts in the body of people with Fabry disease.
調査の概要
詳細な説明
In Fabry disease, the enzyme α-galactosidase A is deficient. AMT-191 is an investigational gene therapy that encodes a recombinant serotype 5 based adeno-associated viral vector (rAAV5). AMT-191 is designed to target the liver for production of the enzyme α-galactosidase A (αGAL). AMT-191 is delivered via a single (one-time) intravenous (IV) infusion.
In this first-in-human study of AMT-191, three dose levels will be tested. All eligible participants will receive AMT-191 at one of the dose levels; there is no placebo in this study. The starting dose level is decided based on accepted rules for dose translation from preclinical (animal) studies to humans. Subsequent dose cohort levels are decided based on the review of safety, tolerability, and PK/PD results by an Independent Data Monitoring Committee and in agreement with the Sponsor.
Participants will be monitored through study site visits, blood tests, imaging questionnaires, and other assessments as per the study protocols.
研究の種類
入学 (推定)
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:uniQure
- 電話番号:1-866-520-1257
- メール:medinfo@uniqure.com
研究連絡先のバックアップ
- 名前:Christy Quintana, Director, Clinical Operations
- 電話番号:734-680-7773
- メール:medinfo@uniqure.com
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35233
- 募集
- The Kirklin Clinic Of University of Alabama Birmingham Hospital
-
コンタクト:
- Christina Desruisseau, BSN
- 電話番号:205-975-2935
- メール:csingleton@uabmc.edu
-
主任研究者:
- Eric Wallace, MD
-
-
California
-
Los Angeles、California、アメリカ、90095
- 募集
- University of California Los Angeles (UCLA)
-
主任研究者:
- Nicola Longo, MD
-
コンタクト:
- Kimberly L. Schweigman
- メール:KSchweigman@mednet.ucla.edu
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30322
- 募集
- Emory University School of Medicine
-
主任研究者:
- William Wilcox, MD
-
コンタクト:
- Dawn Laney
- 電話番号:404-778-8518
- メール:dawn.laney@emory.edu
-
-
Illinois
-
Chicago、Illinois、アメリカ、60611
- 募集
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
主任研究者:
- Carlos E Prada, MD
-
コンタクト:
- Carolyn Rasmussen, MS Genetic Counseling
- 電話番号:312.227.6763
- メール:crasmussen@luriechildrens.org
-
コンタクト:
- Esperanza Mendoza
- メール:eemendoza@luriechildrens.org
-
-
Minnesota
-
Minneapolis、Minnesota、アメリカ、55455
- 募集
- MHealth Fairview University of Minnesota Medical Center East Bank
-
コンタクト:
- Melissa Fetterley, BSN
- 電話番号:612-672-5151
- メール:Melissa.Fetterley@fairview.org
-
コンタクト:
- Brenda Diethelm-Okita, Masters
- メール:dieth001@umn.edu
-
主任研究者:
- Chester B Whitley, MD
-
-
New York
-
New York、New York、アメリカ、10029
- 募集
- NYC Health + Hospitals/Metropolitan
-
主任研究者:
- Maryam Banikazemi
-
コンタクト:
- Alla Pinkhasova
- 電話番号:(917) 796-8272
- メール:pinkhasa4@nychhc.org
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45229
- 募集
- Children's Hospital Medical Center
-
主任研究者:
- Robert J. Hopkin, MD
-
コンタクト:
- Laurie Bailey
- メール:Laurie.Bailey@cchmc.org
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、アメリカ、15224
- 募集
- UPMC Children's Hospital of Pittsburgh
-
コンタクト:
- Jennifer Baker
- 電話番号:412-692-6378
- メール:Jennifer.Baker@chp.edu
-
主任研究者:
- Damara Ortiz, MD
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84108
- 募集
- University of Utah, Clinical and Translational Sciences Institute
-
コンタクト:
- Carrie Bailey, Bachelor of Science
- 電話番号:801-587-3605
- メール:carrie.bailey@hsc.utah.edu
-
コンタクト:
- Jenny Billy
- メール:jenny.billy@hsc.utah.edu
-
主任研究者:
- Brian Shayota, MD, MPH
-
-
Virginia
-
Fairfax、Virginia、アメリカ、22030
- 募集
- Lysosomal & Rare Disorders Research and Treatment Center, Inc
-
主任研究者:
- Ozlem Goker-Alpan
-
コンタクト:
- Lauren Noll
- 電話番号:(571) 732-4655
- メール:LNoll@ldrtc.org
-
コンタクト:
- BreAnna Davis
- メール:BDavis@ldrtc.org
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Key Inclusion Criteria:
-
Male of age ≥ 18 years and ≤65 years
-
Confirmed clinical diagnosis of classic Fabry disease (FD) defined as:
- Absent or minimal αGAL A enzyme activity < 1% of mean normal measured in plasma regardless of variant status; OR
- α-galactosidase A (GLA) pathogenic or likely pathogenic variant associated with classic FD phenotype identified on molecular genetic testing with plasma αGLA A enzyme activity below lower bound of the reference range (as measured at trough enzyme replacement therapy [ERT] levels).
-
eGFR ≥ 40 mL/min/1.73 m2
-
Participant agrees to use a condom during sexual intercourse with any female partner who could become pregnant
-
Suboptimal response after at least 12 months of enzyme replacement therapy (ERT) treatment. Suboptimal response is defined as plasma lyso-Gb3 ≥ 2.3 nanograms per milliliter (ng/mL) at Screening and one or both of the following:
- Persistent moderate or severe neuropathic pain (intermittent or continuous) over a period of at least 3 months prior to consent
- Presence of gastrointestinal symptoms (abdominal cramping, constipation, or diarrhea), reported by the Participant as moderate or severe and that are either persistent or occurring two or more times over the 12 weeks prior to consent
-
Weight ≤ 120 kilograms (kg) and ≥ 45 kg
-
Able and willing to provide informed consent
-
Agrees to have no vaccinations within 6 weeks prior to and 6 weeks after dosing with AMT-191 unless allowed by stud protocol
Key Exclusion Criteria:
-
Any allergic hypersensitivity reaction to ERT or infusion reaction in the 12 months prior to consent that was of severity grade 3 or above based on Common Terminology Criteria for Adverse Events (CTCAE v5.0) and required emergency intervention for hypertension/hypotension to stabilize blood pressure or hypoxia OR any other life-threatening complication.
-
Proteinuria, with random urine protein/creatinine ratio (rUPCR) ≥1 mg/mg at Screening
-
Any previous treatment with investigational drug within 3 months prior to first Screening assessment
-
Any previous treatment with gene therapy
-
Any anticipated participation in interventional studies for the treatment of FD
-
Current use of chaperone therapy such as migalastat (Galafold®)
-
Malignancy within 5 years of Screening, except for basal or squamous cell carcinoma of the skin
-
Presence of chronic, active, or latent infection with hepatitis B or C, human immunodeficiency virus (HIV), or tuberculosis (TB) as assessed at the screening visit.
-
Active or ongoing infection or any other significant concurrent, uncontrolled medical condition including, but not limited to, renal, hepatic, cardiovascular, hematological, GI, endocrine (such as diabetes mellitus with poor glycemic control), pulmonary, neurological, cerebral, or psychiatric disease, alcoholism, drug dependency, or any other psychological disorder that could, in the opinion of the Investigator, risk the safety of the Participant, or interfere with adherence to the protocol procedures or interpretation of results
-
Evidence of any liver disease, including hepatitis, fibrosis, cirrhosis of the liver, neoplastic lesion, or any known medical condition that could impact the intended transduction of the vector and/or expression and activity of the protein
-
History of kidney transplantation or currently on hemodialysis or peritoneal dialysis
-
Moderately severe to severe cardiovascular disease, history of stroke or transient ischemic attacks within 12 months prior to Screening, history of ventricular tachycardia, history of or detection of other significant arrhythmia during Screening; significant thromboembolic disease history; or history of thrombotic risk resulting in current use of anticoagulant/antiplatelet agents.
-
Uncontrolled hypertension, defined as systolic blood pressure >140 millimeters of mercury (mmHg) (inclusive) and/or diastolic blood pressure outside the range of 60 to 85 mmHg (inclusive) at Screening, confirmed on at least 2 repeated measurements
-
Patients taking blood pressure medication to control blood pressure or proteinuria (eg, angiotensin-converting enzyme [ACE] inhibitors and angiotensin II receptor blockers [ARBs]) and have been titrated to a stable dose for at least 3 months prior to Screening are allowed in the study.
-
Glycated hemoglobin (HbA1c) at Screening ≥7%
-
Contraindication to systemic corticosteroid therapy or immunosuppressive therapy
-
Chronic steroid use, defined as ≥ 3 months of oral corticosteroid use within 12 months prior to Screening
-
Screening laboratory values for renal and liver function that meet or exceed any of the following:
- Alanine transaminase (ALT) > 1.5 x upper limit of normal for the testing laboratory (ULN)
- Aspartate aminotransferase (AST) > 1.5 x ULN
- Total Bilirubin > ULN (except if this is caused by Gilbert disease)
- Alkaline phosphatase (ALP) > ULN
- Creatinine > 2 x ULN
- Direct bilirubin > ULN
- Albumin < 30 g/L
- Gamma-glutamyl transferase (GGT) > ULN
- Alpha-fetoprotein > 20 ng/mL unless cause is known and does not meet any other exclusion criteria
-
Screening laboratory values for hematologic and coagulation function that meet any of the following:
- Hemoglobin < lower limit of normal (LLN) (as per reference laboratory ranges)
- Platelet count < 150 x1000/μl
- International normalized ratio (INR) >1.1
- Soluble terminal complement complex (sC5b-9)>ULN
-
Significant anatomical abnormalities on renal ultrasound such as the presence of only 1 kidney, significant differences in kidney sizes between the right and left kidneys >1.5 centimeters (about 0.59 inch), or presence of kidney cysts
-
Pre-existing ocular disease and/or intraocular pressure >21 mmHg at Screening unless referred for formal ophthalmology review and cleared b ophthalmologist to commence prednisone
-
To be (re)-assessed on Day 0 prior to planned infusion:
- Active systemic bacterial, viral, or fungal infection
- ALT or AST ≥ 1.5 x ULN
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:用量範囲コホート 1
|
A recombinant serotype 5 based adeno-associated viral vector (AMT-191) for one-time intravenous (IV) administration will be investigated in this study. This recombinant AAV5-based vector contains a coding deoxyribonucleic acid (DNA) sequence for human α-galactosidase A. Delivery of AMT-191 to the systemic circulation is expected to result in a therapeutic effect by promoting the liver expression of the lysosomal enzyme GLA in plasma levels in patients with Fabry disease. |
|
実験的:用量範囲コホート 2
|
A recombinant serotype 5 based adeno-associated viral vector (AMT-191) for one-time intravenous (IV) administration will be investigated in this study. This recombinant AAV5-based vector contains a coding deoxyribonucleic acid (DNA) sequence for human α-galactosidase A. Delivery of AMT-191 to the systemic circulation is expected to result in a therapeutic effect by promoting the liver expression of the lysosomal enzyme GLA in plasma levels in patients with Fabry disease. |
|
実験的:用量範囲コホート 3
|
A recombinant serotype 5 based adeno-associated viral vector (AMT-191) for one-time intravenous (IV) administration will be investigated in this study. This recombinant AAV5-based vector contains a coding deoxyribonucleic acid (DNA) sequence for human α-galactosidase A. Delivery of AMT-191 to the systemic circulation is expected to result in a therapeutic effect by promoting the liver expression of the lysosomal enzyme GLA in plasma levels in patients with Fabry disease. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
FD 患者における AMT-191 の異なる用量レベルの静脈内投与の安全性と忍容性を評価する
時間枠:60ヶ月
|
60ヶ月
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Characterize the vector shedding of intravenously-administered AMT-191
時間枠:60 Months
|
Duration of vector deoxyribonucleic acid (DNA) shedding present in blood, saliva, feces, semen, and urine. |
60 Months
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Arian Pano, MD, MPH、Clinical Development and Program Lead, uniQure biopharma, B.V.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- CT-AMT-191-01
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。